Loading Events

Upcoming Events

Events Search and Views Navigation

April 2021

Redeye Orphan Drugs Seminar – April 2021

April 28 @ 11:15 - 11:35

Ascelia Pharma's Chief Medical Officer, Carl Bjartmar will present at Redeye Orphan Drugs Seminar. The presentation will be live streamed, to register to the event: https://www.redeye.se/events/802433/theme-orphan-apr-28th

Find out more »

May 2021

Annual General Meeting 2021

May 5 @ 14:00 - 16:00
Find out more »

Interim Report Q1 2021 (January-March 2021)

May 12 @ 08:00

Report will be released at 8.00am CET and conference call at 10:00am CET  

Find out more »

ABGSC Life Science Summit

May 25

Ascelia Pharma will be presenting at ABGSC Life Science Summit

Find out more »

August 2021

Half-year report 2021 (April-June 2021)

August 19 @ 08:00

Report will be released at 8.00am and conference call at 10.00am CET

Find out more »

November 2021

Interim report 9M (January-September 2021)

November 4 @ 08:00

Report will be released at 8.00am CET and conference call at 10.00am CET

Find out more »

February 2022

Full year report 2021 (January-December 2021)

2022-02-10 @ 08:00

Report will be released at 8.00am CET and conference call at 10.00am CET

Find out more »
+ Export Events

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway.

Headquarter is in Malmö, Sweden, and the company’s shares are listed on Nasdaq Stockholm (ticker: ACE)

Download our fact sheet: Ascelia Pharma Factsheet Dec 2020

Events